• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    C

    Centre Hospitalier de la Côte Basque

    EST. 1979
    246论文总数
    1,730引用总数

    论文量&引用量时间轴

    机构学者

    论文(246)

    年份
    起
    –
    止
    排序
    1Plasma Exchange for Severe Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Emulation of a Target Trial
    Anne-Claire Sanna, Ségolène Gendreau,Cyrielle Desnos, Romain Lombardi,Jolan Malherbe, Dimitri Titeca-Beauport, Florian Reizine,Guillaume Louis, Kladoum Nassarmadji, Julien Campagne, Jean-Philippe Martellosio,Alban Deroux,

    RATIONALE:Patients with severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)-related diffuse alveolar hemorrhage (DAH) face high mortality. In the PEXIVAS trial, plasma exchange (PLEX) did not reduce death or end-stage kidney disease, but only 9% had severe DAH. OBJECTIVES:This study aimed to assess whether PLEX lowers mortality in patients with severe DAH. METHODS:We emulated a target trial using retrospective data from a national multicenter cohort of patients with severe AAV-related DAH. The primary endpoint was 30-day mortality after intensive care unit (ICU) admission, analyzed using a Cox model adjusted for prespecified confounders. MEASUREMENTS AND MAIN RESULTS:We included 184 patients (median age 66 [53-75] years; 51% female; 51% with granulomatosis with polyangiitis; 53% MPO (Myeloperoxydase)-ANCA positive). Of these, 144 (78.3%) received PLEX, and 40 (21.7%) did not. Baseline characteristics were similar, except for more severe renal impairment (creatinine 357 vs 171 µmol/L, P = .01) and more frequent cyclophosphamide use (77% vs 55%, P = .01) in the PLEX group. Severity at ICU admission (median Simplified Acute Physiology Score II score: 42) and mechanical ventilation needs (54%) were comparable between groups. At 30 days, overall survival was 85%. No significant difference in mortality was observed between the PLEX and no-PLEX groups: 30-day survival was 85% (95% CI, 81-90) with PLEX vs 88% (95% CI, 77-96) without (hazard ratio, 1.23; 95% CI, 0.57-3.89). Secondary outcomes were also similar. CONCLUSIONS:In this emulated target trial, PLEX did not reduce 30-day mortality in patients with severe AAV-related DAH.

    2026American journal of respiratory and critical care medicine(2026)
    引用
    AI阅读
    加入学术空间
    2Real-world Use of Second-Generation Integrase Strand Transfer Inhibitors (INSTI) As Switch Therapy in the Prospective ANRS-CO3-AquiVIH-NA Cohort
    O Leleux, A Peyrouny-Mazeau, A Perrier, M Hessamfar, G Le Moal, D Neau, L Alleman, C Cazanave, E Lazaro, P Duffau, A Riché, Y Gérard,

    OBJECTIVES:To characterize real-world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)-based regimens with a focus on treatment persistence, effectiveness (HIV-1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. METHODS:People living with HIV from the prospective ANRS-CO3-AquiVIH-NA cohort, who switched from effective antiretroviral treatment (ART) to a BIC- or DTG-based regimen between 2018 and 2021, were eligible for analysis. RESULTS:A total of 2275 people living with HIV were included (52% receiving B/F/TAF, 8% DTG/3TC/ABC, 18% DTG/RPV, 22% DTG/3TC) with a median age of 53-56 years and a comorbidity prevalence of 71%-75% across treatment groups (chronic kidney disease (CKD) 15%-25%, diabetes mellitus 15%-19%, hypertension 57%-64%). Viral suppression rates at month 18 (LOCF, last observation carried forward) using a missing-equals-excluded (M = E) approach were 97% on B/F/TAF, 95% on DTG/3TC/ABC, 97% on DTG/RPV and 96% on DTG/3TC. Discontinuation rates were 16.5% for B/F/TAF, 37.5% for DTG/3TC/ABC, 16.7% for DTG/RPV and 17.3% for DTG/3TC, driven by adverse events in 5.6%, 12.5%, 5.6% and 6.1%, respectively. Comorbidity incidence rates/1000 person years in those free of the respective disease were 39 for hypertension, 22 for diabetes mellitus, 13 for cardiovascular events and 5 for CKD. CONCLUSIONS:In this real-world cohort, treatment persistence 18 months after therapy switch was similar for B/F/TAF, DTG/RPV and DTG/3TC, but significantly lower for DTG/3TC/ABC. All regimens maintained high levels of viral suppression. Furthermore, the cohort illustrates the disease burden experienced by middle-aged and elderly people living with HIV and highlights the importance of adapting ART to the specific needs of this population.

    2026HIV medicine(2026)
    引用
    AI阅读
    加入学术空间
    3Exploring Medical Students’ Discussions on Transcultural Care in France: a Qualitative Study
    Rahmeth Radjack,Anaïs Ogrizek,Amalini Simon, Grace Nong, Agathe Beranger, Adil Mouhab,Marie-Aude Piot, Mathilde Lambert,Marie Rose Moro

    Background Academic instruction on the impact of culture on health care—specifically cultural representations of illness-related needs and diverse treatments of the body and mind—is rare in France. Such instruction is common in other countries with significant immigration, notably Canada and the USA. The reception of this teaching by medical students needs to be explored in the French context, where the consideration of cultural diversity is often controversial or perceived as taboo due to universalist republican traditions. Objectives We aimed to explore the experiences and reflections of second- and third-year medical students regarding the cultural dimension of the physician–patient relationship, focusing on their clinical work, patient-student interactions, and perceptions of migrant patients within the context of a transcultural elective course. Methods Four group discussions were conducted during the first and last sessions of an elective course titled "Transcultural approach to the physician-patient relationship" at our University medical school. The study included 35 medical students in 2023, and an additional focus group of 9 students in 2025 to explore the consistency of the emerging themes. Discussions were audio-recorded, transcribed, and analyzed using inductive reflexive thematic analysis. Results Our qualitative analysis of the transcripts identified four main themes: (1) the place of the mother tongue at the hospital; (2) equity and humanity in caring for the vulnerable in the face of institutional dysfunction; (3) the balance between professional neutrality and the use of cultural identity as a resource in the care relationship; and (4) students’ evolving reflections on their professional positioning. Discussion The group discussions highlighted students' evolving reflections regarding cultural prejudices, the cultural dimensions of care, and the role of interpreters. Students collectively negotiated meanings and professional postures. The pedagogical approach, which alternated between theoretical input and reflexive group discussions, appeared to encourage a process of decentering. Conclusion Group discussion is an appropriate format for a transcultural course among medical students early in their training, allowing them to focus on overarching themes and foundational concepts. This study highlights the relevance of developing structural teaching on these issues for medical students to foster culturally safe care.

    2026
    引用
    AI阅读
    加入学术空间
    4First- and Second-Year Outcomes after Nirsevimab Immunization.
    Amélie Gabet,Epiphane Kolla, Ludovic Tréluyer,Marion Bertrand,Marie-Joelle Jabagi, Olivia Weill, Antoine Rachas,Valérie Olié,Mahmoud Zureik

    Importance:The consistency of nirsevimab effectiveness across consecutive seasons and its broader clinical protective effects remain to be fully characterized. Objective:To assess whether first-season effectiveness of nirsevimab against respiratory syncytial virus (RSV)-lower respiratory tract infection (LRTI)-related hospitalizations is maintained during a new RSV season, whether the effectiveness persists beyond the first season, and whether nirsevimab exposure is associated with hospitalizations for non-RSV infections and asthma during the first and second years of follow-up. Design, Setting, and Participants:This cohort study analyzed 2 nationwide matched cohorts using the French National Health Data System, including infants born in metropolitan France before the 2023 and 2024 immunization campaigns. Infants receiving nirsevimab were matched 1:1 to unimmunized infants. Both cohorts were followed up for 1 year after immunization, with an additional second year of follow-up for the 2023 cohort. Data analysis was performed from February 2023 to August 2025. Exposures:Single dose of nirsevimab. Main Outcomes and Measures:RSV-LRTI-related, non-RSV infection, and asthma hospitalizations were assessed using weighted Cox proportional hazards models. Results:This cohort study included 74 672 infants in 2023 and 175 526 in 2024. At baseline, the mean (SD) age of immunized infants was 4.5 (2.0) months in the 2023 cohort; 19 633 (52.6%) were male and 17 703 (47.4%) were female. The mean (SD) age of the 2024 cohort was 4.8 (2.2) months; 44 863 immunized infants (51.1%) were male and 42 900 (48.9%) were female. Among 37 366 infant pairs in 2023 and 87 763 pairs in 2024, RSV-LRTI-related hospitalizations during the first year of follow-up occurred in 299 (0.8%) immunized vs 899 (2.4%) unimmunized infants in 2023 and 456 (0.5%) vs 1711 (1.9%), respectively, in 2024. Nirsevimab was associated with a lower rate of RSV-LRTI-related hospitalization in both the 2023 and 2024 cohort during the first year of follow-up, with effectiveness estimates of 66% (95% CI, 61%-70%) and 72% (95% CI, 69%-75%), respectively. An association with higher rates of hospitalization for ear, nose, and throat (ENT) bacterial infections was observed (2023 cohort: weighted hazard ratio [wHR], 1.36; 95% CI, 1.00-1.84; 2024 cohort: wHR, 1.43; 95% CI, 1.15-1.78). No significant association was observed for other outcomes. During the second year of follow-up, no protective association was observed for RSV-LRTI-related hospitalization (wHR, 1.03; 95% CI, 0.73-1.43). An association with higher rates of hospitalization for ENT (wHR, 1.56; 95% CI, 1.10-2.22) and asthma (wHR, 1.24; 95% CI, 1.05-1.46) was observed. Conclusions and Relevance:This study found that nirsevimab was associated with a substantial reduction in RSV-LRTI-related hospitalizations during the first year across both the 2023-2024 and 2024-2025 seasons. It was not associated with reduced hospitalizations due to non-RSV infections or asthma, nor during the second year of follow-up.

    2026JAMA pediatrics(2026)
    引用
    AI阅读
    加入学术空间
    5Characterisation of Early-Onset Pancreatic Adenocarcinoma Molecular Profile Compared to Average-Onset Pancreatic Adenocarcinoma (CARAPAC): A Systematic Review and a Meta-Analysis.
    Mathias Brugel, Vivien Riviere, Audrey Hubert, Léonie Langanay,Olivier Bouche,Michaël Genin, Victoria Gauthier, Jean-Baptiste Oudart

    BACKGROUND:Early-onset pancreatic adenocarcinoma (EOPA), defined as the diagnosis of pancreatic adenocarcinoma before the age of 50, is increasingly reported and may differ molecularly from average-onset pancreatic adenocarcinoma (AOPA). Understanding these differences is essential for precision medicine in this poor-prognosis malignancy. METHODS:A systematic review and meta-analysis were conducted following PRISMA guidelines. Studies published between 2015 and 2025 reporting molecular data on EOPA and/or AOPA were identified. Comparative studies stratified by age group for molecular alterations were included in the meta-analysis. Quality assessment was performed using the JBI checklist. This study aimed at systematically review and meta-analyse existing data comparing the molecular landscape of EOPA and AOPA, and evaluate whether EOPA constitutes a distinct molecular subgroup of pancreatic adenocarcinoma. RESULTS:Thirty-nine articles were included in the systematic review, of which eight met criteria for meta-analysis. KRAS mutations were significantly less frequent in EOPA than in AOPA (OR = 0.61; 95%CI [0.43-0.86], p = 0.005). No significant differences were observed for TP53, CDKN2A, SMAD4, or BRCA1/2 alterations. Sensitivity analyses confirmed the robustness of the KRAS finding. Study heterogeneity was moderate (I2 = 40%). Quality assessment revealed substantial variability in design, molecular methods, and reporting standards. CONCLUSIONS:EOPA is enriched in KRAS wild-type tumours. This profile may offer alternative therapeutic opportunities, including RNA-based fusion detection, inclusion in targeted therapy trials, and suggest alternative oncogenic pathways for a proportion of this subpopulation. Standardised definitions, consistent molecular reporting, and exploration of age-specific risk factors are critical to improve understanding and management of EOPA.

    2026Pancreatology official journal of the International Association of Pancreatology (IAP) et al(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 246 篇论文

    合作机构(100)

    巴黎医院公共援助合作论文 30
    Centre Hospitalier Universitaire de Bordeaux合作论文 25
    Institut Bergonié合作论文 15
    波尔多大学合作论文 14
    法国国家健康与医学研究院合作论文 10
    Centre Hospitalier Universitaire de Rennes合作论文 10
    Institute Paoli-Calmettes合作论文 10
    Centre Hospitalier Universitaire de Limoges合作论文 10
    Centre Hospitalier Universitaire de Toulouse合作论文 9
    University Hospital Medical Center at Treichville合作论文 9

    机构统计